IndieBio
IndieBio is an accelerator firm established in 2014 and based in San Francisco, California, with an additional office in New York. It specializes in startups that utilize synthetic biology to address significant global challenges. IndieBio runs four-month accelerator programs aimed at both companies and teams with innovative ideas, focusing on seed-stage and early-stage investments. The firm typically invests $250,000, providing $50,000 in exchange for eight percent equity in biotech startups, with the possibility of an additional $25,000 as a convertible loan note. IndieBio prioritizes investments in businesses that leverage biology as the core of their technology, particularly in life sciences, biotechnology, and related fields. The firm favors teams with a minimum of two co-founders and is open to investing in startups from various geographical locations.
Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical products aimed at controlling challenging crop diseases, pests, and weeds. Utilizing patented protein evolution technology, the company has created a peptide and RNA interference (RNAi) delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform allows for advanced protein engineering through continuous laboratory evolution and other methods, such as phage display. This technology enhances researchers' capabilities in control, reporting, recording, simulation, and remote access, positioning Innatrix as a leader in sustainable agricultural solutions.
Innatrix is an agricultural biotechnology company focused on developing innovative biological and chemical products aimed at controlling challenging crop diseases, pests, and weeds. Utilizing patented protein evolution technology, the company has created a peptide and RNA interference (RNAi) delivery platform that offers eco-friendly alternatives for crop protection. Innatrix's proprietary automated platform allows for advanced protein engineering through continuous laboratory evolution and other methods, such as phage display. This technology enhances researchers' capabilities in control, reporting, recording, simulation, and remote access, positioning Innatrix as a leader in sustainable agricultural solutions.
Avalo is a biotechnology company focused on enhancing crop resilience through innovative gene discovery and control techniques. By employing interpretable machine learning, Avalo accelerates the identification of genes in plants, thereby facilitating the development of improved agricultural crops. The company's artificial intelligence-based platform is designed to uncover the biological origins of traits essential for future agriculture, such as drought tolerance, water-use efficiency, and nutrient density. This advancement in gene discovery not only aids researchers in validating and predicting crop quality but also addresses the challenges posed by a changing climate, contributing to a healthier and more sustainable agricultural landscape.
Avalo is a biotechnology company focused on enhancing crop resilience through innovative gene discovery and control techniques. By employing interpretable machine learning, Avalo accelerates the identification of genes in plants, thereby facilitating the development of improved agricultural crops. The company's artificial intelligence-based platform is designed to uncover the biological origins of traits essential for future agriculture, such as drought tolerance, water-use efficiency, and nutrient density. This advancement in gene discovery not only aids researchers in validating and predicting crop quality but also addresses the challenges posed by a changing climate, contributing to a healthier and more sustainable agricultural landscape.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.